基利德公司撤销了TROPiCS-04试验未能显示生存率的改善后的Trodelvy膀癌药物. Gilead withdraws Trodelvy bladder cancer drug after TROPiCS-04 trial fails to show survival improvement.

Gilead Science在TROPiCS-04号确认试验后撤回了膀胱癌药物Trodelvy, 未能表明它改善了患者存活率。 Gilead Sciences has withdrawn its bladder cancer drug Trodelvy after a confirmatory trial, TROPiCS-04, failed to show it improved patient survival. 由于其瘤缩小效果,最初在2021年获得FDA加速批准,Trodelvy的撤回反映了FDA撤销有条件批准的趋势. Initially granted accelerated FDA approval in 2021 for its tumor-shrinking effects, Trodelvy's withdrawal reflects a trend of the FDA revoking conditional approvals. Gilead的初级癌症治疗仍为Yescarta, 预计今年将获得有关三联负乳癌Trodelvy的进一步数据。 Gilead's primary cancer treatment remains Yescarta, while further data on Trodelvy for triple-negative breast cancer is anticipated this year.